No Major Updates Presented at Ziopharm’s R&D Day
On Thursday, March 11, Ziopharm held their R&D day (presentation) where they presented no major updates for their CD19 rapid manufacturing (RPM) CAR-T program or their personalized / library TCR-T approach. Nevertheless, management reiterated that their CD19 RPM cells could potentially cost $10,000, with a dose x100 lower than traditional autologous CAR-Ts. Finally, Ziopharm presented initial results from the CD19 RPM CAR-T investigator-initiated trials, highlighting the CAR-T’s acceptable tolerability profile (see image below).